drugset / Trial / NCT03904745

Effect of Oxytocin Antagonists on Implantation Success Rates of Frozen-thawed Embryo Transfer

NCT03904745

RandomizedParallel-groupSingle-blindTreatment

Summary

Uterine contraction has a negative impact on implantation and pregnancy rates. Inhibition of oxytocin receptors decreases uterine contraction frequency both on pregnant and non-pregnant women. Atosiban has been studied as an oxytocin antagonist to decrease uterine contraction frequency in order to increase implantation and pregnancy rates in assisted reproduction. Previous studies have studied 37,5mg total dose which was used both before and during embryo transfer, and found atosiban to be effective in increasing implantation and pregnancy rates. We aim to use a single dose of 6,75mg atosiban before embryo transfer, in order to decrease the dose and cost and possibly introduce a simpler protocol. Our study will also be the first randomized clinical study which investigates the effect of atosiban on frozen-thawed embryo transfer cycles.

Timeline

Start
2020-12-21
Primary completion
2021-07-30
Completion
2021-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Atosiban Other / unclassified 6.75 mg Intravenous

Indications